221 related articles for article (PubMed ID: 11979888)
21. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Shirai N; Furuta T; Sugimoto M; Nakamura A
Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
[No Abstract] [Full Text] [Related]
22. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
23. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Bardou M
Rev Prat; 2001 Apr; 51(7):789-95. PubMed ID: 11387678
[No Abstract] [Full Text] [Related]
24. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Tazuma S; Horikawa Y; Nakamura M
Dig Dis Sci; 2005 Jul; 50(7):1202-6. PubMed ID: 16047460
[TBL] [Abstract][Full Text] [Related]
25. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
[No Abstract] [Full Text] [Related]
26. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
29. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Itagaki F; Homma M; Yuzawa K; Fukao K; Kohda Y
Transplant Proc; 2002 Nov; 34(7):2777-8. PubMed ID: 12431607
[No Abstract] [Full Text] [Related]
30. [Primary care for GEDR].
Takeda H
Nihon Rinsho; 2004 Aug; 62(8):1499-503. PubMed ID: 15344540
[TBL] [Abstract][Full Text] [Related]
31. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
32. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
33. [A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Ohkusa T; Watanabe M
Nihon Rinsho; 2001 Feb; 59(2):323-7. PubMed ID: 11218406
[TBL] [Abstract][Full Text] [Related]
34. Recurrent anaphylaxis linked to pantoprazole.
Kollmeier AP; Eddleston J; Zuraw BL; Christiansen SC
J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
[No Abstract] [Full Text] [Related]
35. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
36. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
[TBL] [Abstract][Full Text] [Related]
37. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Sharara AI
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
[TBL] [Abstract][Full Text] [Related]
38. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Miura M
Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
[TBL] [Abstract][Full Text] [Related]
39. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
40. Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
Wada F; Murase K; Isomoto H; Soda H; Takeshima F; Omagari K; Mizuta Y; Tsukamoto K; Murata I; Kohno S
J Int Med Res; 2002; 30(4):413-21. PubMed ID: 12235924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]